ReviewThe FEBS journal2026
Redirecting TRIM21 with TRIMTACs for the targeted degradation of multimeric proteins.
Review in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PROTACs (PROteolysis-Targeting Chimeras) are heterobifunctional small molecules that induce proximity between E3 ubiquitin ligases and target proteins to drive target protein ubiquitination and proteasomal degradation. TRIM21 is an intracellular Immunoglobulin G (IgG) receptor and E3 ubiquitin ligase that functions to degrade cytoplasmic antibody-coated viral particles. Genetic approaches have redirected TRIM21 towards a wide range of cellular proteins, and mechanistic studies have demonstrated TRIM21's preference for degrading multimeric substrates such as protein aggregates. Recently, the first small molecules targeting TRIM21 have been reported, including some that have been elaborated into PROTACs (TRIMTACs) that degrade multimeric proteins. In this State-of-the-Art review, we describe the unique biology of TRIM21, detail recently reported TRIMTACs, and suggest future opportunities for TRIMTACs to impact targeted protein degradation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.